{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:55:10Z","timestamp":1763754910633,"version":"3.45.0"},"reference-count":18,"publisher":"Oncology Nursing Society (ONS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2009,12,1]]},"DOI":"10.1188\/09.cjon.s2.19-23","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T21:30:52Z","timestamp":1263504652000},"page":"19-23","source":"Crossref","is-referenced-by-count":10,"title":["Management of mTOR Inhibitor Side Effects"],"prefix":"10.1188","volume":"13","author":[{"given":"Patricia A.","family":"Creel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2009,11,30]]},"reference":[{"issue":"2","key":"1","first-page":"1105","article-title":"Cancer treatment-induced oral mucositis","volume":"27","author":"D. Alterio","year":"2007","journal-title":"Anticancer Research"},{"issue":"8","key":"2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"J. Bellmunt","year":"2008","journal-title":"Annals of Oncology"},{"issue":"2","key":"3","first-page":"1","article-title":"Renal cell carcinoma: State-of-the-art diagnosis and treatment","volume":"2","author":"R. Bukowski","year":"2007","journal-title":"Clinical Oncology News"},{"issue":"23","key":"4","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"H. Cohen","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"5","first-page":"107","article-title":"Cytochrome p450: New nomenclature and implications","volume":"57","author":"M. Cupp","year":"1998","journal-title":"American Family Physicians"},{"issue":"4","key":"6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/04.ONF.S4.13-23","article-title":"Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment","volume":"31","author":"J. Eilers","year":"2004","journal-title":"Oncology Nursing Forum"},{"issue":"10","key":"7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies","volume":"139","author":"T. Hutson","year":"2008","journal-title":"Oncologist"},{"issue":"4","key":"8","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"A. Jemal","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.ftd.0000175911.70172.2e","article-title":"The role of therapeutic monitoring of everolimus in solid organ transplantation","volume":"27","author":"V. Mabasa","year":"2005","journal-title":"Therapeutic Drug Monitoring"},{"issue":"4","key":"10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1188\/08.CJON.639-646","article-title":"Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma","volume":"12","author":"L. Malizzia","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"9637","key":"11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled, phase III trial","volume":"372","author":"R. Motzer","year":"2008","journal-title":"Lancet"},{"key":"12","unstructured":"National Cancer Institute. (2003). <i>Common Terminology Criteria for Adverse Events [v.3.0]. Therapy evaluation program.<\/i> Retrieved January 21, 2008, from <a target=\"_blank\" href='http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf'>http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf<\/a>"},{"key":"13","unstructured":"National Comprehensive Cancer Network. (2008). Clinical Practice Guidelines in Oncology\u2122 [v.1.09]: Kidney cancer. Retrieved December 10, 2008, from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"issue":"6","key":"14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/jlts.2001.24645","article-title":"mTOR inhibitors: An overview","volume":"7","author":"P. Neuhaus","year":"2001","journal-title":"Liver Transplantation"},{"key":"15","unstructured":"Novartis Pharmaceuticals. (2009). <i>Afinitor\u00ae<\/i> [Prescribing information]. East Hanover, NJ: Author."},{"key":"16","unstructured":"Tabernero, J., Rojo, F., Burris, H., Casado, E., Macarulla, T., Jones, S., et al. (2005). A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors [Abstract 3007]. Retrieved November 10, 2009, from <a target=\"_blank\" href='http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/23\/16_suppl\/3007'>http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/23\/16_suppl\/3007<\/a>"},{"issue":"1","key":"17","first-page":"6","article-title":"A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line","volume":"7","author":"O. Trubetskoy","year":"2005","journal-title":"APPS Journal"},{"key":"18","unstructured":"Wyeth Pharmaceuticals. (2008). <i>Torisel\u00ae<\/i> [Prescribing information]. Madison, NJ: Author."}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/J216178P04634875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:38Z","timestamp":1763754578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/13\/6\/supplement-december-2009-renal-cell-carcinoma\/management-mtor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,30]]},"references-count":18,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2009,12,1]]}},"alternative-id":["J216178P04634875"],"URL":"https:\/\/doi.org\/10.1188\/09.cjon.s2.19-23","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2009,11,30]]}}}